More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Related News Articles

Headline
The AHA July 2 expressed support for the Resident Physician Shortage Reduction Act (H.R. 3890), bipartisan legislation that would add 14,000 Medicare-funded…
Headline
The House July 3 voted 218-214 to pass the final version of the One Big Beautiful Bill Act (H.R. 1), which enacts many of President Trump’s legislative…
Headline
The Senate narrowly passed the One Big Beautiful Bill Act (H.R. 1) on July 1 by a 50-50 tally, with Vice President J.D. Vance casting the tie-breaking vote.…
Headline
The AHA June 29 sent a letter to senators urging them to amend the budget reconciliation bill before its final passage in the Senate. The Senate version of the…
Chairperson's File
Public
Advocacy is a core part of the work of the AHA, protecting and sustaining what hospitals and health systems need to truly care for our communities. We often…
Perspective
In the next few days, Senate Republican leaders plan to unveil and vote on their updated reconciliation bill, which, as currently constructed, would have far-…